BioStock: Prolight Diagnostics CSO comments on latest data

Supported by the latest data from its Psyros point-of-care system, Prolight Diagnostics is ready to initiate pre-validation trials using fresh whole blood and banked plasma patient samples to measure troponin.
– The lower the detection limit of the system, the more accurately it can measure troponin at the relevant concentrations. This is where Psyros single-molecule counting system has a strong competitive advantage, says Prolight Diagnostics’ CSO Aileen McGettrick.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/prolight-diagnostics-cso-comments-on-latest-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se